Hester exits Texas Lifesciences with ₹2.3 crore sale of final 11% stake
What's the deal? Hester Biosciences has sold its remaining 11% stake in Texas Lifesciences for ₹2.3 crore, completing a full exit from the entity. The move ends the company's minority holding and hands it immediate cash.
What's the endgame? Hester, an Indian veterinary healthcare and vaccines firm, is streamlining its corporate structure. It plans to focus on core poultry vaccines and its growing pet health division, with proceeds likely redeployed into vaccine manufacturing and pet care.
Why now? The sale concludes a multi-year divestment process aimed at cutting exposure to non-core associate companies. In May 2026, Hester reported 14% growth in consolidated revenue, driven by demand for its PPR vaccine in international markets. Poultry vaccine margins expanded 120 basis points in the prior quarter.
What could go wrong? Hester forgoes any dividend income or synergies if Texas Lifesciences scales after the exit. It also faces execution risk in redeploying the ₹2.3 crore and remains dependent on a few core poultry products for top-line stability.
Read more: Sahi
Image credit: Generated with Gemini
